Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,073 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Rocca HB, Janssens S, Tsutsui H, Zhang J, Brueckmann M, Jamal W, Cotton D, Iwata T, Schnee J, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Packer M, et al. Among authors: iwata t. Eur Heart J. 2021 Feb 11;42(6):671-680. doi: 10.1093/eurheartj/ehaa968. Eur Heart J. 2021. PMID: 33459776 Free PMC article. Clinical Trial.
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Packer M, et al. Among authors: iwata t. J Am Coll Cardiol. 2021 Mar 23;77(11):1381-1392. doi: 10.1016/j.jacc.2021.01.033. J Am Coll Cardiol. 2021. PMID: 33736819 Free article. Clinical Trial.
Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial.
Packer M, Januzzi JL, Ferreira JP, Anker SD, Butler J, Filippatos G, Pocock SJ, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Packer M, et al. Among authors: iwata t. Eur J Heart Fail. 2021 Sep;23(9):1529-1538. doi: 10.1002/ejhf.2256. Epub 2021 Jun 21. Eur J Heart Fail. 2021. PMID: 34053177 Free PMC article. Clinical Trial.
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
Januzzi JL Jr, Zannad F, Anker SD, Butler J, Filippatos G, Pocock SJ, Ferreira JP, Sattar N, Verma S, Vedin O, Schnee J, Iwata T, Cotton D, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Januzzi JL Jr, et al. Among authors: iwata t. J Am Coll Cardiol. 2021 Sep 28;78(13):1321-1332. doi: 10.1016/j.jacc.2021.07.046. J Am Coll Cardiol. 2021. PMID: 34556318 Free article. Clinical Trial.
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
Januzzi JL Jr, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Verma S, Vedin O, Iwata T, Brueckmann M, Packer M, Anker SD; EMPEROR-Preserved Trial Study Group. Januzzi JL Jr, et al. Among authors: iwata t. JACC Heart Fail. 2022 Jul;10(7):512-524. doi: 10.1016/j.jchf.2022.05.004. Epub 2022 Jun 1. JACC Heart Fail. 2022. PMID: 35670067 Free article.
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
Böhm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T, Ponikowski P, Wanner C, Zannad F, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Böhm M, et al. Among authors: iwata t. J Am Coll Cardiol. 2022 Jul 5;80(1):1-18. doi: 10.1016/j.jacc.2022.04.040. J Am Coll Cardiol. 2022. PMID: 35772911 Free article. Clinical Trial.
2,073 results